Radical concurrent chemoradiotherapy for esophageal carcinoma

doi:10.3760/cma.j.issn.1673-422X.2016.01.014

Abstract

Abstract: In National Comprehensive Cancer Network guideline, patients with the clinical stages of ⅠBⅢA esophageal neoplasms should be given radical PF regimen (cisplatin + 5fluorouracil) concurrent chemoradiotherapy. The majorization PF and radiation dosage are studied by some scholars in China and abroad, and the local control rate and survival rate are improved, adverse reaction is within a controllable range. In recent years, some new drugs such as capecitabine, paclitaxel, docetaxel, pemetrexed and carboplatin also show their advantages in radical concurrent chemoradiotherapy.

Key words: Esophageal neoplasms, Radiotherapy, Drug therapy, Capecitabine

Liu Yongxuan, Feng Xiaoshan. Radical concurrent chemoradiotherapy for esophageal carcinoma[J]. Journal of International Oncology, 2016, 43(1): 49-52.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI:10.3322/caac.21262. ［2］董颖, 杨文君. 消化道恶性肿瘤流行病学特征与发病现状分析［J］. 医学综述, 2014, 20(3): 429-431. DOI:10.3969/j.issn.1006-2084.2014.03.015. ［3］ Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 11-30. DOI:10.3322/caac.21166. ［4］ Rackley T, Leong T, Foo M, et al. Definitive chemoradiotherapy for oesophageal cancera promising start on an exciting journey［J］. Clin Oncol (R Coll Radiol), 2014, 26(9): 533-540. DOI:10.1016/j.clon.2014.06.001. ［5］ Chen W, Zheng R, Zhang S, et al. Report of cancer incidence and mortality in China, 2010［J］. Ann Transl Med, 2014, 2(7): 61. DOI:10.3978/j.issn.2305-5839.2014.04.05. ［6］ Tong DK, Law S, Kwong DL, et al. Current management of cervical esophageal cancer［J］. World J Surg, 2011, 35(3): 600-607. DOI:10.1007/s00268-010-0876-7. ［7］ Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation［J］. Cancer, 2012, 118(10): 26322640. DOI:10.1002/cncr.26586. ［8］ Blum MA, Taketa T, Sudo K, et al. Chemoradiation for esophageal cancer［J］. Thorac Surg Clin, 2013, 23(4): 551-558. ［9］ Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial［J］. Lancet Oncol, 2014, 15(3): 305-314. ［10］ Tougeron D, Richer JP, Silvain C. Management of esophageal adenocarcinoma［J］. J Visc Surg, 2011, 148(3): e161-170. DOI:10.1016/j.jviscsurg.2011.05.008. ［11］ Akutsu Y, Matsubara H. The significance of lymph node status as a prognostic factor for esophageal cancer［J］. Surg Today, 2011, 41(9): 11901195. DOI:10.1007/s00595-011-4542-y. ［12］ Kato K, Muro K, Minashi K, et al. Phase Ⅱ study of chemoradiotherapy with 5fluorouracil and cisplatin for stage Ⅱ-Ⅲ esophageal squamous cell carcinoma: JCOG Trial (JCOG 9906)［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3): 684690. DOI:10.1016/j.ijrobp.2010.06.033. ［13］ Kato K, Nakajima TE, Ito Y, et al. Phase Ⅱ study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage Ⅱ-Ⅲ esophageal carcinoma［J］. Jpn J Clin Oncol, 2013, 43(6): 608-615. DOI:10.1093/jjco/hyt048. ［14］ Yamashita H, Omori M, Takenaka R, et al. Involvedfield irradiation concurrently combined with nedaplatin/5fluorouracil for inoperable esophageal cancer on basis of (18)FDGPET scans: a phase Ⅱ study［J］. Radiother Oncol, 2014, 113(2): 182-187. DOI:10.1016/j.radonc.2014.11.004. ［15］ Lee SJ, Ahn BM, Kim JG, et al. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study［J］. J Korean Med Sci, 2009, 24(1): 120125. DOI:10.3346/jkms.2009.24.1.120. ［16］ Xing L, Liang Y, Zhang J, et al. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer［J］. J Cancer Res Clin Oncol, 2014, 140(5): 867-872. DOI:10.1007/s00432-014-1615-5. ［17］尹雪, 刘杰, 田金徽. 紫杉醇联合顺铂同步放化疗治疗中晚期食管癌的Meta分析［J］. 肿瘤防治研究, 2012, 39(7): 851-854. DOI:10.3971/j.issn.10008578.2012.07.022. ［18］ Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma［J］. Dis Esophagus, 2010, 23(3): 253-259. DOI:10.1111/j.14422050.2009.01003.x. ［19］ Tang HR, Ma HF, An SM, et al. A phase Ⅱ study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma［J］. Am J Clin Oncol, 2014, In press. ［20］ Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study［J］. Med Oncol, 2012, 29(5): 3017-3023. DOI:10.1007/s12032-012-0228-6. ［21］ Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5fluorouracil (DCFR) in advanced esophageal cancer: a phase 2 trial (KDOG 0501P2)［J］. Int J Radiat Oncol Biol Phys, 2014, 89(4): 872-879. DOI:10.1016/j.ijrobp.2014.03.030. ［22］ Li BS, Gong HY, Huang W, et al. Phase Ⅰ study of concurrent selective lymph node late course accelerated hyperfractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma［J］. Dis Esophagus, 2011, 24(4): 251257. DOI:10.1111/j.14422050.2010.01130.x. ［23］ Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients［J］. Ann Oncol, 2014, 25(3): 638-643. DOI:10.1093/annonc/mdt589. ［24］ Shen ZT, Wu XH, Li B, et al. Nedaplatin concurrent with threedimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma［J］. World J Gastroenterol, 2013, 19(48): 9447-9452. DOI:10.3748/wjg.v19.i48.9447. ［25］张发恩, 韦嵩, 韦春琳, 等. 三维适形放疗联合奥沙利铂加卡培他滨同步化疗治疗食管癌的疗效分析［J］. 实用癌症杂志, 2014, 29(2): 174-176. DOI:10.3969/j.issn.1001-5930.2014.02.019. ［26］ Chang H, Shin SK, Cho BC, et al. A prospective phase Ⅱ trial of S1 and cisplatinbased chemoradiotherapy for locoregionally advanced esophageal cancer［J］. Cancer Chemother Pharmacol, 2014, 73(4): 665-671. DOI:10.1007/s00280-013-2371-y.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[6]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[9]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[10]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[11]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[12]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[13]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[14]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[15]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.